Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital

Sponsor
Sohag University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04977089
Collaborator
(none)
100
1
12
8.3

Study Details

Study Description

Brief Summary

Chronic coronary syndrome (CCS) is a newly described classification devised by the European Society of Cardiology (ESC) 2019 to replace the term "Stable Coronary Artery Disease (CAD).

The main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical, pharmacological, and pathophysiological entities.

Using this new term, the disease atherosclerosis manifests as CAD is categorized into Acute Coronary Syndrome (ACS) and CCS.

The main focus of introducing the concept of CCS is on the fact that CAD is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases.

Dyslipidemia is recognized as a prominent risk factor for cardiovascular (CV) disease.

It is characterized by an elevation of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or triglycerides (TG) and reduced serum high-density lipoprotein cholesterol (HDL-C) concentration .

Genetically determined and metabolically induced disturbances in lipid metabolism, as manifested in several types of dyslipidemia, have been shown to be causally related to the development of coronary artery disease (CAD).

A diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events.

Independent predictors of recurrent CVD events or death include age, smoking, hypertension (HTN), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of medications recommended by current treatment guidelines.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: lipid profile test .

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital
Actual Study Start Date :
Aug 1, 2020
Anticipated Primary Completion Date :
Aug 1, 2021
Anticipated Study Completion Date :
Aug 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Ischemic heart disease patients .

Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.

Diagnostic Test: lipid profile test .
Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )

Outcome Measures

Primary Outcome Measures

  1. Dyslipidemia in chronic coronary syndrome [one year]

    Pattern of dyslipidemia among patients with chronic coronary syndromes at sohag university hospital.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • All patients have chronic coronary disease at Sohag University hospital who recieve drugs of anti hyperlipidemia .
Exclusion Criteria:
  • Patients with first attack of acute coronary syndrome .

  • Young patients <18 years .

  • Old patients >65 years.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sohag University Hospital Sohag Egypt

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Islam Mohamed Farrag, resident doctor at internal medicine department sohag university hospital, Sohag University
ClinicalTrials.gov Identifier:
NCT04977089
Other Study ID Numbers:
  • Soh-Med-21-07-01
First Posted:
Jul 26, 2021
Last Update Posted:
Jul 26, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 26, 2021